Morphologic and clinicopathologic features of lung squamous cell carcinomas expressing Sox2
- PMID: 23086772
- DOI: 10.1309/AJCP05TTWQTWNLTN
Morphologic and clinicopathologic features of lung squamous cell carcinomas expressing Sox2
Abstract
Sox2 amplification was recently reported as a common event in squamous cell carcinomas (SCCs) occurring at different anatomic sites including the lung. The objective of the study was to determine morphologic and clinicopathologic characteristics of lung SCCs with respect to Sox2 protein expression and gene amplification. One hundred forty-seven surgically treated non-small cell lung carcinomas were analyzed for Sox2 gene amplification by using fluorescence in situ hybridization and protein expression using immunohistochemical analysis. SCC showed more frequent Sox2 protein expression (52/66; 79%) than adenocarcinomas (ADC) (14/76; 18%) (P < .0001). Similarly, Sox2 amplification was more frequent in SCCs (52/70; 72%) than in ADCs (6/77; 8%) (P < .0001). Sox2 protein expression was associated with better overall survival in SCC (66 vs 14 months; P =.048). SCC with basaloid differentiation and severe nuclear atypia exhibited more intense Sox2 protein expression than other tumors. Sox2 appears to be an important gene in lung squamous cell carcinogenesis that in particular drives the development of poorly differentiated tumors.
Similar articles
-
SOX2 amplification is a common event in squamous cell carcinomas of different organ sites.Hum Pathol. 2011 Aug;42(8):1078-88. doi: 10.1016/j.humpath.2010.11.010. Epub 2011 Feb 21. Hum Pathol. 2011. PMID: 21334718
-
Expression of MET and SOX2 genes in non-small cell lung carcinoma with EGFR mutation.Oncol Rep. 2011 Oct;26(4):877-85. doi: 10.3892/or.2011.1349. Epub 2011 Jun 15. Oncol Rep. 2011. PMID: 21687954
-
Significance of EGFR protein expression and gene amplification in non-small cell lung carcinoma.Am J Clin Pathol. 2006 Jun;125(6):860-5. doi: 10.1309/H5UW-6CPC-WWC9-2241. Am J Clin Pathol. 2006. PMID: 16690485
-
[Clinicopathological study on primary lung cancer--immunohistochemical expression of p53 suppressor gene and bcl-2 oncogene in relation to prognosis].Rinsho Byori. 1996 Jan;44(1):32-41. Rinsho Byori. 1996. PMID: 8691638 Review. Japanese.
-
Association of SOX2 and Nestin DNA amplification and protein expression with clinical features and overall survival in non-small cell lung cancer: A systematic review and meta-analysis.Oncotarget. 2016 Jun 7;7(23):34520-31. doi: 10.18632/oncotarget.9145. Oncotarget. 2016. PMID: 27150062 Free PMC article. Review.
Cited by
-
SOX2 expression is associated with FGFR fusion genes and predicts favorable outcome in lung squamous cell carcinomas.Onco Targets Ther. 2015 Oct 19;8:3009-16. doi: 10.2147/OTT.S91293. eCollection 2015. Onco Targets Ther. 2015. PMID: 26527886 Free PMC article.
-
Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells.Cancers (Basel). 2018 Jul 27;10(8):248. doi: 10.3390/cancers10080248. Cancers (Basel). 2018. PMID: 30060526 Free PMC article. Review.
-
Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease.PLoS One. 2014 Apr 15;9(4):e95303. doi: 10.1371/journal.pone.0095303. eCollection 2014. PLoS One. 2014. PMID: 24736592 Free PMC article.
-
Sox2 and βIII-Tubulin as Biomarkers of Drug Resistance in Poorly Differentiated Sinonasal Carcinomas.J Pers Med. 2023 Oct 18;13(10):1504. doi: 10.3390/jpm13101504. J Pers Med. 2023. PMID: 37888115 Free PMC article.
-
NSCLC Driven by DDR2 Mutation Is Sensitive to Dasatinib and JQ1 Combination Therapy.Mol Cancer Ther. 2015 Oct;14(10):2382-2389. doi: 10.1158/1535-7163.MCT-15-0077. Epub 2015 Jul 23. Mol Cancer Ther. 2015. PMID: 26206333 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
